
TVGN Stock Forecast & Price Target
TVGN Analyst Ratings
Bulls say
Tevogen Bio Holdings is a promising clinical-stage company with a potential breakthrough therapy, TVGN 489, that targets COVID-19 and its lingering symptoms. With a diversified pipeline of products targeting infectious diseases, cancers, and neurological disorders, and a focus on precision T cell therapies, the company has strong growth potential. However, there are inherent risks in the biotech industry, including clinical and regulatory uncertainty and potential legal and financial challenges, that could impact the success of the company. Nonetheless, with its innovative approach and strong management team, Tevogen Bio Holdings is well-positioned for future success.
Bears say
Tevogen Bio Holdings is facing potential trading pressures due to the upcoming reverse split, creating a temporary vacuum in demand for shares and reducing liquidity in the market. The company's dilution risk and delayed timing of commercialization also contribute to our negative outlook on the stock. Additionally, while the potential acquisition of a Contract Research Organization may offer strategic and financial benefits, there is no guarantee of completion and it remains subject to various conditions.
This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.
TVGN Analyst Forecast & Price Prediction
Start investing in TVGN
Order type
Buy in
Order amount
Est. shares
0 shares